A Randomized, Double-Blind, Placebo-Controlled, Parallel, 3-Arm Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCl ER Tablets in Prurigo Nodularis Patients
Phase of Trial: Phase II/III
Latest Information Update: 10 Jun 2017
At a glance
- Drugs Nalbuphine (Primary)
- Indications Prurigo nodularis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Trevi Therapeutics
- 13 Oct 2016 Results published in Trevi Therapeutics media release.
- 13 Sep 2016 Status changed from active, no longer recruiting to completed.
- 02 Jun 2016 Planned End Date changed from 1 Jul 2016 to 1 Aug 2016.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History